Literature DB >> 9081209

Allogeneic stem cell transplantation for multiple myeloma.

W I Bensinger1, D Buckner, G Gahrton.   

Abstract

High-dose chemotherapy (with or without total body irradiation) followed by allogenic marrow transplantation is curative for some patients with advanced multiple myeloma. A relatively high transplant-related mortality, however, limits the wider application of this approach. The challenge for future studies will be to develop less toxic preparative regimens, more efficient ways to prevent infection and graft-versus-host disease, and methods to enhance the graft-versus-leukemia effect of allografts.

Entities:  

Mesh:

Year:  1997        PMID: 9081209     DOI: 10.1016/s0889-8588(05)70420-2

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  4 in total

Review 1.  Current drug therapy for multiple myeloma.

Authors:  Y W Huang; A Hamilton; O J Arnuk; P Chaftari; R Chemaly
Journal:  Drugs       Date:  1999-04       Impact factor: 9.546

2.  Treatment of bendamustine and prednisone in patients with newly diagnosed multiple myeloma results in superior complete response rate, prolonged time to treatment failure and improved quality of life compared to treatment with melphalan and prednisone--a randomized phase III study of the East German Study Group of Hematology and Oncology (OSHO).

Authors:  W Pönisch; P S Mitrou; K Merkle; M Herold; M Assmann; G Wilhelm; K Dachselt; P Richter; V Schirmer; A Schulze; R Subert; B Harksel; N Grobe; E Stelzer; M Schulze; A Bittrich; M Freund; R Pasold; Th Friedrich; W Helbig; D Niederwieser
Journal:  J Cancer Res Clin Oncol       Date:  2006-01-10       Impact factor: 4.553

Review 3.  The role of high-dose chemotherapy supported by hematopoietic stem cell transplantation in patients with multiple myeloma: implications for nursing.

Authors:  Anna Liza Rodriguez; Joseph D Tariman; Toreend Enecio; Stella Marie Estrella
Journal:  Clin J Oncol Nurs       Date:  2007-08       Impact factor: 1.027

4.  Long-term outcome of patients with multiple myeloma after autologous hematopoietic cell transplantation and nonmyeloablative allografting.

Authors:  Marcello Rotta; Barry E Storer; Firoozeh Sahebi; Judith A Shizuru; Benedetto Bruno; Thoralf Lange; Edward D Agura; Peter A McSweeney; Michael A Pulsipher; Parameswaran Hari; Richard T Maziarz; Thomas R Chauncey; Frederick R Appelbaum; Mohamed L Sorror; William Bensinger; Brenda M Sandmaier; Rainer F Storb; David G Maloney
Journal:  Blood       Date:  2008-11-17       Impact factor: 22.113

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.